92952-46-0

Basic information

• Product Name: 6,78,9 TETRAHYDROBEZ(G) ISATIN
• Synonyms: 6,78,9 TETRAHYDROBEZ(G) ISATIN;6,7,8,9-Tetrahydrobenz[g]isatin;1H,2H,3H,6H,7H,8H,9H-cyclohexa[g]indole-2,3-dione;1H-Benz[g]indole-2,3-dione,6,7,8,9-tetrahydro-;6,7,8,9-Tetrahydro-1H-benz[g]indole-2,3-dione
• CAS NO: 92952-46-0
• Molecular Formula: C₁₂H₁₁NO₂
• Molecular Weight: 201.224
• Mol File: 92952-46-0.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.303
• Storage Temp.: 2-8°C
• PKA: 10.43±0.20(Predicted)
• CAS DataBase Reference: 6,78,9 TETRAHYDROBEZ(G) ISATIN(CAS DataBase Reference)
• NIST Chemistry Reference: 6,78,9 TETRAHYDROBEZ(G) ISATIN(92952-46-0)
• EPA Substance Registry System: 6,78,9 TETRAHYDROBEZ(G) ISATIN(92952-46-0)

Safety Data

• Hazardous Substances Data: 92952-46-0(Hazardous Substances Data)

Usage

General Description

6,78,9 Tetrahydrobez(g) isatin is a chemical compound with the molecular formula C14H11NO2. It is a heterocyclic compound that contains a benzene ring fused to a five-membered nitrogen-containing ring. 6,78,9 TETRAHYDROBEZ(G) ISATIN has been studied for its potential pharmaceutical and medicinal properties, including its use as an antitubercular agent. It has also been shown to have anti-inflammatory and analgesic properties, making it a candidate for the development of new drugs. Additionally, 6,78,9 Tetrahydrobez(g) isatin has been investigated for its potential as an antimicrobial and anticancer agent. Its unique structure and potential medicinal properties make it an interesting compound for further research and development in the field of pharmaceutical chemistry.

Upstream product

• 79-37-8 oxalyl dichloride 
• 6271-86-9 5-aminotetralin hydrochloride 
• 92952-47-1 hydroxyimino-acetic acid-(5,6,7,8-tetrahydro-[1]naphthylamide) 
• 2217-41-6 1-amino-5,6,7,8-tetrahydronaphthalene 
• 92952-47-1 C₁₂H₁₄N₂O₂ 

Downstream Products

• 110536-50-0 Benzoic acid [2-oxo-1,2,6,7,8,9-hexahydro-benzo[g]indol-(3E)-ylidene]-hydrazide 
• 924633-94-3 3-acetylamino-2-(4-chloro-benzyl)-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic acid 
• 851546-73-1 2-(3,4-Dichlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid 
• 851546-71-9 3-Hydroxy-2-(4-trifluoromethoxy-benzyl)-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic acid 
• 851546-61-7 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid 
• 924633-93-2 3-amino-2-(4-chloro-benzyl)-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic acid 
• 721942-75-2 1-amino-5,6,7,8-tetrahydro-[2]naphthoic acid 
• 1067187-34-1 3-hydroxy-2-(2-phenylpropan-2-yl)-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid 
• 1067187-45-4 3-hydroxy-2-(1-phenylethyl)-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid 
• 1067186-60-0 3-hydroxy-2-(1-phenylcyclopropyl)-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid 

Relevant articles and documents

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

Methods and Compositions for Treatment of Scleritis and Related Disorders

The present teachings relate to the field of anti-inflammatory substances and more particularly to compounds that are useful for the treatment of scleritis, a scleritis symptom, or a scleritis-related disorder. In one aspect, methods of treating scleritis, a scleritis symptom, or a scleritis-related disorder generally include administering to a subject a compound of Formula I: or a pharmaceutically acceptable salt, hydrate or ester thereof, wherein W1, W2, R1, L, X, Y, Z, and n1 are defined as described herein.

Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands

A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile, carbo-alkoxy, carbo-aryloxy and carboxyl; and A is a 5- or 6-membered ring optionally containing one or more heteroatoms wherein the atoms of the ring A, other than the unsaturated carbon atoms of the phenyl ring to which the ring A is fused, are saturated or unsaturated, and pharmaceutically acceptable salts, addition compounds and prodrugs thereof; and the use thereof in therapy, particularly as an agonist or antagonist of a 5HT receptor, particularly a 5HT2C receptor, for instance in the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.